Revenue distribution by sectors:

• Diagnostics: 35%
• Medical Technology: 30%
• Nutrition: 20%
• Generics: 15%

TOP 3 markets and their percentage shares:

• USA: 40%
• China: 15%
• Germany: 10%

Abbott Laboratories generates its revenues from four main sectors: Diagnostics, Medical Technology, Nutrition, and Generics. The largest share of revenue comes from the Diagnostics sector, followed by Medical Technology.

Geographically, the U.S. market is the most significant for Abbott, followed by China and Germany. These markets are crucial for the growth and stability of the company, as they represent both large and growing healthcare markets.

Production sites of Abbott Laboratories:

Abbott Laboratories operates numerous production facilities worldwide. The main locations are in the USA, Ireland, Germany, Singapore, and China.

Abbott Laboratories is a globally active company that manufactures a variety of products in the areas of diagnostics, medical devices, nutrition, and branded generics. The production sites are strategically distributed across different continents to serve the demand in the respective regions and to benefit from logistical and cost advantages.

In the USA, significant production sites are located in states such as Illinois and Ohio. In Ireland, Abbott has a strong presence, especially in the manufacturing of diagnostic products. Germany is another important location, particularly for the production of medical devices. Singapore and China play a central role in Asian production and supply.

This global distribution enables Abbott to efficiently respond to regional market demands while optimizing production costs.

Revenue growth: 8.5% (2024) Research and development investments: 2.5 billion USD (2024)

Abbott Laboratories pursues a growth strategy that strongly focuses on innovation and diversification. The company continuously invests in research and development to bring new products to the market in the fields of medical technology, diagnostics, and nutrition. These investments amount to approximately 2.5 billion USD, highlighting the importance of R&D for the company.

Another focus is on geographical expansion, particularly in high-growth markets in Asia and Latin America. Abbott leverages strategic partnerships and acquisitions to expand its market presence and tap into new customer segments.

In addition, Abbott is focusing on digitizing and automating its processes to achieve efficiency gains and increase production capacities. These measures are intended not only to reduce costs but also to enhance the company's responsiveness to market changes.

Main raw materials: Plastics, glass, metals, chemicals

Main supplying countries: China, Germany, USA, India

Abbott Laboratories imports a variety of raw materials and materials necessary for the production of its medical devices and pharmaceutical products. These include plastics and metals, which are often sourced from China and the USA. Glass and special chemicals are often imported from Germany, while India is an important supplier of pharmaceutical raw materials.

Abbott's global supply chain is designed to secure high-quality materials at competitive prices. This enables the company to optimize its production costs while maintaining the high quality standards required for medical products.

Market share in the diagnostics segment: 20% (2024, estimate)
R&D expenses: 2.5 billion USD (2024)
Gross margin: 55% (2024)

Abbott Laboratories has a significant competitive advantage, especially in the diagnostics segment, where the company holds an estimated market share of 20%. This is supported by continuous investments in research and development, which amounted to approximately 2.5 billion USD in 2024. These investments enable Abbott to develop innovative products and differentiate itself from the competition.

The 55% gross margin in 2024 indicates that the company is able to offer its products at competitive prices while achieving high profit margins. This is an indicator of strong operational efficiency and a solid market position.

Abbott Laboratories also benefits from a diversified product portfolio, allowing the company to offset fluctuations in individual segments. This diversification, combined with a strong global presence, helps to strengthen the company's competitive advantage.

Institutional investor share: approx. 75% (estimated for 2025 based on historical data)

Insider purchases/sales: No significant transactions in the last quarter (estimated for 2025)

Abbott Laboratories has traditionally had a high share of institutional investors, which has been around 75% in recent years. This demonstrates the confidence of large investment firms and funds in the company's stability and growth potential.

Regarding insider purchases and sales, there were no significant transactions in the last quarter, indicating a stable trust of the management in the current company strategy. Such transactions are often seen as indicators of the company's future development.

Market share Abbott Laboratories: Estimate 8% (2025)

Main competitors and their market shares:

1. Johnson & Johnson: 12%
2. Roche Holding AG: 11%
3. Pfizer Inc.: 10%
4. Abbott Laboratories: 8%
5. Medtronic plc: 7%
6. Novartis AG: 6%
7. Merck & Co., Inc.: 5%
8. Sanofi: 4%
9. Bristol-Myers Squibb: 3%
10. GlaxoSmithKline: 3%

Abbott Laboratories has a solid market share in the healthcare sector, especially in the fields of medical technology and diagnostics. Abbott's moat lies in its wide range of products, strong brands, and continuous innovations, particularly in the diagnostics sector. This enables the company to compete in a highly competitive market.

Compared to its competitors, Abbott has a moderate moat. Companies like Johnson & Johnson and Roche may have stronger moats due to their larger market shares and extensive research and development resources. These companies benefit from broader diversification and a stronger global presence.

Abbott must continue to invest in research and development and form strategic partnerships to strengthen its competitive position and expand its moat.

Revenue Growth: 8% (2024) Profit Growth: 10% (2024) Research & Development (R&D) Expenses: 2.5 billion USD (2024)

Abbott Laboratories recorded a revenue growth of 8% and a profit growth of 10% in 2024. These positive growth rates indicate a strong operational performance supported by a diversified product range and a solid market presence.

The company continues to invest significantly in research and development, with expenses of 2.5 billion USD in 2024. These investments are crucial for future innovation and the development of new products, especially in the fields of medical technology and diagnostics.

Abbott Laboratories has established itself as a leader in the healthcare industry and benefits from a broad portfolio that includes both established products and innovative solutions. The continuous investments in R&D and strong financial performance suggest that the company is well positioned to achieve future growth.

Overall, Abbott Laboratories could be an attractive investment, especially for investors interested in long-term growth in the healthcare sector.

Dividend yield: 1.8% (estimated for 2025)
Dividend growth: 5% annually (average over the last 5 years)

Abbott Laboratories is known for its reliable dividend policy. The company has consistently paid dividends in recent years and has regularly increased them. The current dividend yield is around 1.8%, which is competitive compared to other companies in the healthcare sector.

Abbott has a long tradition of dividend payments and is considered a dividend aristocrat, meaning it has continuously increased its dividend for over 25 years. This reliability is supported by a strong financial position and stable cash flows, indicating that the dividend policy can continue in the future as well.